Related Experiment Video
Updated: May 5, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: A systematic
Luis Alfonso Zarco1, Andrés Felipe Cárdenas-Cruz2, Óscar Muñoz3
1Neurologist-Neuroimmunologist Student, Master's Program in Multiple Sclerosis, Dresden International University, Dresden, Germany; Associate Professor of Neurology, Neuroscience Department, Division of Neurology, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia.
Background:
Chronic inflammation is a key driver of disability progression in multiple sclerosis (MS). Paramagnetic rim lesions (PRLs), which correspond to imaging markers of chronic active lesions (CALs), have emerged as candidate biomarkers of disease severity. Although associated with progression, the current evidence is limited by small sample sizes, short follow-up periods, and incomplete adjustment for confounding factors.
Objectives:
To evaluate whether PRLs detected by susceptibility-weighted imaging (SWI), filtered phase, or quantitative susceptibility mapping (QSM) using 3T or 7T MRI predict progression independent of relapse activity (PIRA) or disability progression confirmed at 6 months (CDP), as measured by the Expanded Disability Status Scale (EDSS), in adults with MS.
Methods:
We systematically searched PubMed and Embase to identify studies evaluating associations between PRLs and disability progression in MS. Risk of bias was assessed with the Quality In Prognosis Studies (QUIPS) tool, and certainty of evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.
Results:
Five studies including 744 patients were analyzed. The presence of PRLs was associated with a higher risk of PIRA (odds ratio [OR] 2.24; 95 % confidence interval [CI]: 1.17-4.29; p = 0.01) and CDP (OR 2.87; 95 % CI: 1.01-8.1; p = 0.05). In studies with ≤4 years of follow-up, the association with PIRA was stronger (OR 2.84; 95 % CI: 1.72-4.68; p < 0.0001). Certainty of evidence was rated as moderate for PIRA and low for CDP.
Conclusions:
PRLs are associated with an increased risk of MS progression through PIRA. Clinical trials investigating novel disease-modifying therapies (DMTs) that target chronic inflammation and prevent disability progression should consider the presence of PRLs at baseline.
Insights
Paramagnetic rim lesions (PRLs) indicate increased risk of multiple sclerosis (MS) progression, even without relapses. Identifying PRLs at baseline can inform clinical trials for new MS therapies targeting chronic inflammation.
Area of Science:
- Neuroimaging
- Neurology
- Biomarkers
Background:
- Chronic inflammation drives disability in multiple sclerosis (MS).
- Paramagnetic rim lesions (PRLs) are imaging markers of chronic active lesions (CALs) and potential biomarkers for MS severity.
- Existing evidence on PRLs and MS progression is limited by small sample sizes and short follow-up periods.
Purpose of the Study:
- To assess if PRLs detected via MRI predict progression independent of relapse activity (PIRA) or confirmed disability progression (CDP) in MS patients.
- To evaluate PRLs using susceptibility-weighted imaging (SWI), filtered phase, or quantitative susceptibility mapping (QSM) at 3T or 7T MRI.
Main Methods:
- Systematic literature search of PubMed and Embase for studies on PRLs and MS disability progression.
- Quality assessment using the Quality In Prognosis Studies (QUIPS) tool.
- Certainty of evidence graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.
Main Results:
- Analysis of five studies with 744 patients revealed PRLs associated with higher risk of PIRA (OR 2.24) and CDP (OR 2.87).
- The association between PRLs and PIRA was stronger in studies with shorter follow-up (≤4 years, OR 2.84).
- Certainty of evidence was moderate for PIRA and low for CDP.
Conclusions:
- Paramagnetic rim lesions (PRLs) are linked to increased risk of MS progression, particularly PIRA.
- PRLs serve as a potential imaging biomarker for predicting MS disability progression.
- Baseline PRL assessment is recommended for clinical trials targeting chronic inflammation and MS progression.
Related Concept Videos
Magnetic Resonance Imaging
Multiple Sclerosis l: Introduction

